<DOC>
	<DOCNO>NCT02349906</DOCNO>
	<brief_summary>The aim trial describe safety efficacy intravenous ( i.v . ) Treosulfan compare conventional ( myeloablative ) dose i.v . Busulfan , administer part standardise Fludarabine-containing condition regimen contribute PK model permit - conjunction data compare Treosulfan Busulfan adult malignant disease - extend use Treosulfan paediatric population extrapolate efficacy .</brief_summary>
	<brief_title>Treosulfan-based Versus Busulfan-based Conditioning Paediatric Patients With Non-malignant Diseases</brief_title>
	<detailed_description>The prospective clinical phase II protocol MC-FludT.16/NM conduct verify safety efficacy Treosulfan-based conditioning compare Busulfan-based conditioning paediatric patient . Based give clinical experience either Treosulfan-based Busulfan-based conditioning combination Fludarabine increase risk graft failure expect paediatric patient . A potential benefit study patient expect respect probably low non-haematological toxicity treatment compare myeloablative TBI-based condition high-dose Busulfan-based conditioning combination Cyclophosphamide . However , allogeneic HSCT procedure potentially involve serious risk regard severe life-threatening condition like graft versus host disease ( GvHD ) and/or infectious complication well graft failure . In summary , primary goal study evaluate Treosulfan-based myeloablative conditioning regimen alternative child contribute current PK model Treosulfan able finally give age ( body surface area [ BSA ] ) dependent dose recommendation . The treatment regimens give protocol MC-FludT.16/NM base sufficient clinical safety efficacy data . Considering vital indication allogeneic HSCT select patient population , risk-benefit assessment seem favour study conduct . Moreover , plan interim analysis ensure early identification unexpected risk . Therefore , conduct protocol MC-FludT.16/NM consider reasonably justify .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<criteria>1 . Nonmalignant disease indicate first myeloablative allogeneic HSCT , include inborn error metabolism , primary immunodeficiency , haemoglobinopathy bone marrow failure syndrome . 2 . First allogeneic HSCT . 3 . Available match sibling donor ( MSD ) , match family donor ( MFD ) match unrelated donor ( MUD ) . For bone marrow ( BM ) peripheral blood ( PB ) match define least 9/10 allele match four digit type human leucocyte antigen ( HLA ) A , B , C , DRB1 DQB1 antigens . For umbilical cord blood ( UCB ) match define least 5/6 match two digit type HLAA B four digit type DRB1 antigen . 1 . Second later HSCT . 2 . HSCT mismatch donor ( le 9/10 BM/peripheral blood stem cell ( PBSC ) less 5/6 match cord donor ) . 3 . Preterm newborn infant ( &lt; 37 week gestational age ) term newborn infant age 0 27 day time registration . 4 . Obese paediatric patient body mass index weight ( kg ) / [ height ( ) ] ² &gt; 30 kg/m² . 5 . Diagnosis Fanconi anaemia chromosomal breakage disorder , radiosensitivity disorder ( deoxyribonucleic acid ( DNA ) Ligase 4 , Cernunnos Xray repair crosscomplementing protein 4 ( XRCC4 ) like factor ( XLF ) , Nijmegen Breakage Syndrome ( NBS ) ) Dyskeratosis Congenita .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>non-malignant disease , allogeneic stem cell transplantation</keyword>
</DOC>